NasdaqGS:NCNABiotechs
We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
NasdaqGS:VRTXBiotechs
Is Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Latest Stock Performance A Reflection Of Its Financial Health?
Vertex Pharmaceuticals' (NASDAQ:VRTX) stock is up by a considerable 29% over the past three months. Given the company's...
NasdaqGM:IMPLBiotechs
Impel NeuroPharma, Inc. (NASDAQ:IMPL): Are Analysts Optimistic?
We feel now is a pretty good time to analyse Impel NeuroPharma, Inc.'s ( NASDAQ:IMPL ) business as it appears the...
NasdaqGM:TCRXBiotechs
Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
NasdaqGS:SRPTBiotechs
Investors push Sarepta Therapeutics (NASDAQ:SRPT) 17% lower this week, company's increasing losses might be to blame
Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shareholders have seen the share price descend 19% over the month. But that...
NasdaqGS:RGNXBiotechs
As REGENXBIO Inc.'s (NASDAQ:RGNX)) market cap dropped by US$52m, insiders who sold US$6.1m worth of stock were able to offset their losses
Insiders at REGENXBIO Inc. ( NASDAQ:RGNX ) sold US$6.1m worth of stock at an average price of US$37.79 a share over the...
NasdaqGS:NTRABiotechs
With Natera, Inc.'s (NASDAQ:NTRA)) price down 10% this week, insiders might find some solace having sold US$13m worth of shares earlier this year.
Insiders at Natera, Inc. ( NASDAQ:NTRA ) sold US$13m worth of stock at an average price of US$96.36 a share over the...
NasdaqGM:ITOSBiotechs
Even though iTeos Therapeutics (NASDAQ:ITOS) has lost US$118m market cap in last 7 days, shareholders are still up 13% over 1 year
There's no doubt that investing in the stock market is a truly brilliant way to build wealth. But if you choose that...
NasdaqGS:ENTABiotechs
While shareholders of Enanta Pharmaceuticals (NASDAQ:ENTA) are in the black over 5 years, those who bought a week ago aren't so fortunate
Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders have seen the share price descend 20% over the month. But at...